We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
For the record,
23 Sept goes xd.
1.8p/share,
14 Oct payment
If not mistaken, we have a dividend to receive this month.
Some more appointments, covered in the blog on LHS....
https://www.keyoptions.com/virolens/
Bit of a pull back in SP. Probably more macro, inflation related as across several tech stocks. Divi soon.
Trek
Nearly there, £500m mcap.
We should start seeing some institutional interest once we get through £3.
Usual caveats
Trek
Well reading between the lines they must have flogged a few!
“The mission of IVRC is to foster collaborative research among the Virolens™ community generally and in the field of varieties of COVID testing methods and screening in particular. It is planned to begin with regular informal meetings of IVRC in October 2021.
“......The IVRC plans to organize weekly seminars, where members and non-members can sign up and present their news, updates, study papers and so on, and to discuss them with the group. The research group will also arrange update sessions on the most recent papers and research matters for COVID-19, again with a particular focus on the Virolens™ Technology. The IVRC plans to organize workshops, conferences, guest lectures, and offer results from clinical trials, research and white papers.
The IVRC includes researchers and Virolens™ owners from Asia, Australasia, Latin Americas, Africa and the Middle East as well as international organizations and the representation of i-Abra, the Virolens™ technology founding company.
These partners have agreed to coordinate their research programmes to address agreed research needs, share results and together deliver new and improved Virolens™ testing and use strategies for current SARS-CoV-2 and future strains. It is hoped that the IVRC will be able to discuss new strains of the infection, including vaccines, diagnostics and therapeutics, together with other procedures and/or key scientific information and tools to support risk analysis and disease control.......”
Published yesterday....
https://www.keyoptions.com/virolens/
Trek
Hi Alas,
Virolens is a ‘turnstile test’. There is no other on the market yet but others are likewise progressing holographic imaginary for detecting pathogens.
There really isn’t a sufficient moat to ‘Warren Buffet’ this business. It’s high tech, relatively low margin work. It’s usp is it’s high end tech, worldwide coverage and ability to deliver bespoke products at volume with excellent customer links. You can see all the blurb on the webpage. There are many others in this market.
It’s a great recovery play and is moving under its own steam. A Virolens announcement will supercharge the SP!
LFT’s have their place but they really would have worked better in conjunction with covid passports. The narrative around testing and passports seems to have taken a back seat to vax and booster vax and get on with it. The UK is becoming a paradigm for that model.
Even with the narrative changing things like cruise ships, airports, schools, doctors surgeries, police stations, nursing homes etc Could cope better with a rapid covid test than a cumbersome up to 15min LFT. At the moment it’s really down to the individual to decide if they take an LFT before visiting granny even if both are double jabbed.
We know Virolens has MHRA approval. We know of the Scotland trials and Heathrow. We know the financial results included numbers ‘aside from Virolens’ but other than that it’s been very quiet.
If I was looking to enter now I would be looking at the order book in the results, the outlook, the divi cover and BoD skill with acquisitions.
If you think it can stand-alone on those fundamentals then you get Virolens as a potential share price super charger event!
Without the potential of Virolens I wouldn’t have invested. Ironically now I have I have been very pleased with this companies performance especially dealing with supply side constraints.
Usual caveats
Trek
....continued
will, or perhaps should a huge rollout of testing to place controls be initiated. And that is where the anomoly lies.
We know the benefits of the the TTG system, we know that there are partners involved, but we do not know the extent to which extremely rapid testing has a take up and this will only be known from a political and perhaps WHO led initiative.
Sorry to ramble.
Disclaimer - I own shares in TTG some of which are held in ISA wrapper and some in my dealing accounts.
Every so often I look at an individual company and try and work out if, with the information I have now determine if it is a company in which to invest for the first time, sell as the company no longer has the appeal it had or hold for the reasons that persuaded me to bung some money at in the first place.
I'm going to disclose a little personal information at this point.
I am well educated but not a high flyer. In fact, my current salary is below the national average and a little above the minimum wage. I have neither inherited money nor won any lottery. My wealth is simply from living within my means, working bloody hard and squirrelling whatever I can save for a rainy day. I have drawn everything I managed to save for rainy days on 3 occasions. I now find myself, the consequence of house price inflation, more good decisions than bad to have accumulated substantial capital (property) and cash (investments) yet am income poor. I actually have an IHT problem (almost £2m nett worth) but with a salary of slightly over £16,000. I have liquid assets (shares in public companies) of almost £800k that as a portfolio is generating considerably over half of my income by way of dividends and considerably more by way of capital growth. I make, on average 12 portfolio changes each year. This is generally one disposal (in whole) and 2 purchases at my average bargain price (£15,000) - 4 sales and 8 purchases. I top this up with my regular investments from income £850 each month. I have few outgoings (no mortgage) but do spend a lot of money on my motorcycles, horses, fine wine, art and skiing.
Disclaimer out of the way.
Is there a compelling reason to buy shares in TTG right now? And before that is considered, perhaps it might be worth asking the question, "Does TTG have an economic moat?". More simply put, "can I lose money?".
For new investors, I suspect the answers are No, No and Yes. But why therefore am I going against logic and added a few more share today - don't get excited it was only £500 worth (please see previous disclaimer)? Well, Mr Market gets things wrong from time to time and I believe that the shares in TTG are not priced to reflect the future, only the past.
We are, whether we like it or not, at the stage in the pandemic where there are medicines to protect. This protection has been rolled out to varying extent to the richest countries and restrictions to movement are beginning to be reduced. I suspect that by the end of September (6 weeks time), for many of us, life will have returned to pretty normal conditions and that is when our guard should be greatest.
Although local protection has been afforded in part to developed nations, spread has not been contained. And to control spread requires testing. My hunch therefore is that only once morbidity (spread of disease) has been controlled ...
In part I agree.... in that the UK market APPEARS to be undervalued. That has been the case since the UK went the the polls to vote to leave the EEC/EC/Eu whatever it is called. Rather than consider the UK under valued, I feel that it has been overlooked, and, frankly, rightly so. However, once it became clear that not only has the UK remained a viable place in which to do business, it has actually coped remarkably well with the rollout of the vaccination program to control the mortality from morbidity that Covid 19 and its variants have presented.
That TTG is an excellent company on its own merits with decent managers is gratifying. This is shown in the continuing improvement in the share price. I am not a fan of short termism and simply selling up the moment that a bidder appears. Not that an uplift in the SP is not welcome, it simply means that there might be a void in my portfolio, the bidder may not be listed and I have to look for the next winner to fill that gap. And sometimes there is a knock on effect to impact other holdings. The consequence (for me) might mean a partial re-composition of my portfolio.
Yet, I have done exactly that a few weeks ago - sold up holdings in VTY and PSN to sit on 6% cash (very unusual for me as I like to be fully invested). I also took some profits off the table in Nvidia by disposing of 30% of my holding as I am not convinced that the purchase of ARM will go ahead. This added even more cash. My decision was to weight my portfolio to smaller UK companies, specifically TSTL and MTU. To address the partial void with NVDA, I purchased shares in ASML and although bought my stake in MTU to 8% portfolio, I added some shares in MINI for good measure. Time will tell whether I am correct or not.
In the meanwhile, although we start to close the month and September is usually flat, August has been pretty good for my portfolio and I hope that yours has also fared well. At this stage, I have a paper uplift of slightly under 11% and expect to complete the year (if things go according to my projections) with a portfolio gain of 18.4% I am expecting 2022 to build on momentum but taper off quite hard from July to the end of the year. 2023 has all the hallmarks of being very flat indeed. But, who knows what opportunities await?
Agree. Very short termism. If it does happen I just hope it's another British listed company
I expect so as FTSE aside many companies are significantly undervalued. Particularly in the small cap space when compared to assets and the build cost.
A t/o only gives a short term lift. Investors holding a high growth divi paying company like TTG would likely be robbed!
Trek
At a time when takeovers of UK assets are running high, is TTG is on someone's shopping list. Surprising if not.
All seemed to go a little pear shaped this afternoon...... I cannot see a compelling reason to sell my shares at the moment, so in the absence of news, plus ca change
Has the SP been a little perkier recently, or is it just me imagining things?
It’s on directors talk.
Trek
Interview, while we endure a little inevitable profit taking before having a go at £3 imo.
https://www.***************************/tt-electronics-record-order-book-and-continued-strong-momentum-interview/4121015762
Trek
I also think, going off the results and future potential as a company, there may well be more money from institutional investors.
I'm not selling at this stage either. Virolens or not this is a good company to be invested in right now.
Solid set of results, and profit, which includes costs regarding Torotel integration and other new factories, good order book, and virolens yet to come. There are still billions not vaccinated yet, it will take years, so only way to guarantee no transmission is through testing. Any news on other regions giving license for these machines will push up share price, 6 more months could be worth the wait.
The results have been well received and, at the risk of seeming perverse, I am wondering how much effect a delayed or no rollout of Virolens would have for the share price. My interpretation is that testing confirms or denies existance of morbidity and vaccination gives protection from mortality consequential from infection. Vaccination does not seem to prevent transmission. Testing remains essential and necessary.
Talk is thus for a booster program to happen this winter in the UK suggesting to me that in the same way that science has determined that lifetime immunity from tetanus is achieved with 3 jabs, over the long term similar conclusion may be reached. And although the rollout of testing machines would not be harmful to the share price of TTG, priority needs to be to provide and support full vaccination to all countries not simply the developed nations.
7% (ish) uplift is very satisfactory, especially based on news. Had it been in isolation, I would be heading for the door!
new 5 year high in SP now!
That should generate a bit of interest on back of results. I am often nervous on results day. I was here at least as so many unknowns. They did well. I guess a bit of a relief rally as well in the mix today!
Virolens on top of this soon, well that will be interesting!
Trek
Yes, very good results.
An encouraging reference to Virolens but no mention of costs incurred, or an initial order.
" The Virolens COVID-19 screening device achieved its first important regulatory milestone in H1, gaining registration with the MHRA in Great Britain. We have now established a product with commercial potential and remain encouraged that active dialogue is continuing with a number of regulators and that commercial potential exists with a range of customers subject to further approvals."
Well looking at these results I think our investment here will do very well. A fantastic relatively low risk growth story. I was concerned about the supply side constraints and inflationary pressures but the BoD have been proactive by extending lead times.
Getting back to levels pre-covid is an outstanding result!
I have only scan read for now will read the whole later. I only saw one reference to Virolens where they took the Virolens numbers out to show organic growth more representatively.
Trek
A large investment I made on 21 July seems to be paying off. So far.
Interesting to note that the SP advanced shortly after the decision to allow fully vaccinated holidaymakers not to quarantine from Europe or US.